Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer

Veronica Ghini, Letizia Laera, Beatrice Fantechi, +6

Cancers

Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial

Maria Carmela Piccirillo, Laura Bonanno, Marina Chiara Garassino, +30

Journal of Thoracic Oncology

Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2

Pierpaolo Correale, G. Campoccia, K.Y Tsang, +11

European Journal of Cancer

Cancer ImmunosurveillanceImmunologyTumor ImmunityTherapeutic VaccineAutoimmunity +8

High-Affinity HLA-A(*)02.01 Peptides from Parathyroid Hormone-Related Protein Generate In Vitro and In Vivo Antitumor CTL Response Without Autoimmune Side Effects

Guido Francini, Antonio Scardino, Kostas Kosmatopoulos, +10

The Journal of Immunology

Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes

Pierpaolo Correale, Maria Grazia Cusi, Marianna Sabatino, +9

European Journal of Cancer

AllergyImmunologyImmunodominanceImmunologic MechanismAntigen Processing +7

Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools

Laura Biganzoli, Anna Rachelle Mislang, Samantha Di Donato, +15

The Journals of Gerontology Series A

Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA

Marzia Del Re, Iacopo Petrini, Francesca Mazzoni, +10

Clinical Lung Cancer

MedicineMalignant Blood DisorderImmunologyPathologyCirculating Cell-free Dna +3

Weekly Low-Dose Docetaxel in Advanced Hormone-Resistant Prostate Cancer Patients Previously Exposed to Chemotherapy

Roberto Petrioli, Daniele Pozzessere, Simona Messinese, +7

Oncology

Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients

Pierpaolo Correale, Daniela Cerretani, Stefania Marsili, +8

European Journal of Cancer

MedicineSystemic 5-Fluorouracil ExposurePharmacologyPharmacotherapyCancer Treatment +2

A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid

Pierpaolo Correale, Simona Messinese, Stefania Marsili, +12

British Journal of Cancer